Effects of first antiretroviral regimen on lipid levels in HIV (+) individuals

• Published in: Journal of chemotherapy (Florence) Vol. 24; no. 1; pp. 38 - 47
• Main Authors: Papadopoulos, A, Pantazis, N, Panagopoulos, P, Kourkounti, S, Xylomenos, G, Chini, M, Petrikkos, G, Sambatakou, H, Ioannidou, P, Kordosis, T, Panos, G, Touloumi, G
• Format: Journal Article
• Language: English
• Published: Firenze Taylor & Francis 01.02.2012; EIFT; Taylor & Francis Ltd
• Subjects: Adolescent; Adult; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiretroviral Therapy, Highly Active; Antiretrovirals; Biological and medical sciences; Cohort Studies; Female; Greece - epidemiology; HIV; HIV - drug effects; HIV Infections - blood; HIV Infections - drug therapy; HIV Infections - epidemiology; HIV Protease Inhibitors - therapeutic use; Human viral diseases; Humans; Immunodeficiencies; Immunodeficiencies. Immunoglobulinopathies; Immunopathology; Infectious diseases; Lipid levels; Lipids - analysis; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Reverse Transcriptase Inhibitors - therapeutic use; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Young Adult; Greece; Human; Immunopathology; Antiretrovirals; Antiretroviral agent; Retroviridae; Lipids; AIDS; Immune deficiency; Lentivirus; Lipid levels; Infection; Virus; HIV; Viral disease; Individual; Antiviral; Human immunodeficiency virus
• ISSN: 1120-009X; 1973-9478
• DOI: 10.1179/1120009X12Z.0000000008

Objective: To evaluate the long-term effects of different boosted protease inhibitors (bPIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs)-based antiretroviral regimens on lipid levels in HIV seropositive individuals who have not received lipid-lowering agents. Methods: Data consisted of 595 patients participating in the population-based Athens Multicenter Cohort Study who were consistently followed up during 1996-2008. Results: In naïve patients, lipid parameters increased sharply during the first 3 months of antiretroviral therapy and reached a plateau level approximately 6-9 months after therapy initiation. The plateau levels remained almost stable for up to 3·5 years. In general, bPIs exerted a more pronounced effect compared to NNRTIs. Conclusions: The administration of PI- or NNRTI-based regimens especially in naïve but also in unboosted PI experienced patients provoked a sharp increase in lipid levels that remained stable in higher levels for more than 3 years.